Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study.
A total of 62 patients at high risk for recurrence of superficial bladder cancer were selected for a study designed to compare the prophylactic efficacy of different doses and schedules of sequential intravesical instillations of epirubicin and interferon-alpha-2b and to evaluate which sequence could enhance the release of cytokines in the urine. Our investigations showed a significant increase in urinary concentrations of interleukins in patients who received the sequential intravesical administration of epirubicin and interferon-alpha-2b. Higher urinary concentrations of interleukins and a lower recurrence rate were detected in patients who received interferon-alpha-2b 24h after epirubicin instillation.
Serretta
V
V
Department of Urology, Civic Hospital, Palermo, Italy.
Corselli
G
G
Piazza
B
B
Lio
D
D
Gervasi
F
F
Salerno
S
S
Pavone-Macaluso
M
M
D000283:Administration, Intravesical; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D007375:Interleukin-1 / Q000652:urine; D007376:Interleukin-2 / Q000652:urine; D015847:Interleukin-4 / Q000652:urine; D007378:Interleukins / Q000652:urine*; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D011994:Recombinant Proteins; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007375:Interleukin-1; D007376:Interleukin-2; D007378:Interleukins; D011994:Recombinant Proteins; D015847:Interleukin-4; D015251:Epirubicin